Diagonal Bio Ab Stock Current Valuation
| DIABIO Stock | 0.03 0 3.05% |
Valuation analysis of Diagonal Bio AB helps investors to measure Diagonal Bio's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Diagonal Bio's price fluctuation is out of control at this time. Calculation of the real value of Diagonal Bio AB is based on 3 months time horizon. Increasing Diagonal Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Diagonal Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Diagonal Stock. However, Diagonal Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0338 | Real 0.0244 | Hype 0.03 | Naive 0.0429 |
The real value of Diagonal Stock, also known as its intrinsic value, is the underlying worth of Diagonal Bio AB Company, which is reflected in its stock price. It is based on Diagonal Bio's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Diagonal Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Diagonal Bio AB helps investors to forecast how Diagonal stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Diagonal Bio more accurately as focusing exclusively on Diagonal Bio's fundamentals will not take into account other important factors: Diagonal Bio AB Company Current Valuation Analysis
Diagonal Bio's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Diagonal Bio Current Valuation | 112.69 K |
Most of Diagonal Bio's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Diagonal Bio AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Diagonal Bio AB has a Current Valuation of 112.69 K. This is much higher than that of the sector and significantly higher than that of the Current Valuation industry. The current valuation for all Sweden stocks is notably lower than that of the firm.
Diagonal Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Diagonal Bio's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Diagonal Bio could also be used in its relative valuation, which is a method of valuing Diagonal Bio by comparing valuation metrics of similar companies.Diagonal Bio is currently under evaluation in current valuation category among its peers.
Diagonal Fundamentals
| Return On Equity | -0.52 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (3.67) % | |||
| Current Valuation | 112.69 K | |||
| Shares Outstanding | 34.77 M | |||
| Shares Owned By Insiders | 14.74 % | |||
| Price To Book | 0.50 X | |||
| Price To Sales | 3.26 X | |||
| Revenue | 407 K | |||
| Gross Profit | (85 K) | |||
| EBITDA | (11.66 M) | |||
| Net Income | (11.66 M) | |||
| Book Value Per Share | 2.39 X | |||
| Cash Flow From Operations | (10.94 M) | |||
| Earnings Per Share | (1.83) X | |||
| Market Capitalization | 21.97 M | |||
| Total Asset | 36.01 M | |||
| Net Asset | 36.01 M |
About Diagonal Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Diagonal Bio AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Diagonal Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Diagonal Bio AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Diagonal Stock
Diagonal Bio financial ratios help investors to determine whether Diagonal Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Diagonal with respect to the benefits of owning Diagonal Bio security.